Rheumnow

New to RheumNow?  Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields.  In this episode, Dr Jack Cush reviews the news, journal articles and FDA warnings from the past week on RheumNow.com A population based Swedish study of birth records shows that antibiotic exposure in first three years of life to be associated with a future risk of JIA, although infections during fetal life or childhood did not increase risk of JIA. #RheumNow https://t.co/Md0zBm5Txl Alendronate may protect against type 2 Diabetes. Data from National Danish Patient Registry, presented at the EASD meeting compared 160k T2DM & 500k controls, T2DM following alendronate adjusted OR=0.64; 0.62-0.66; ⋗8yrs OR=0.47 https://t.co/RYEZodUZtv Analysis of 508 #RA pts (over 10 yrs) in the BeST study shows joint swelling at baseline resulted in half w/ re-swelling later and significantly increased risk of same joint

Merry Christmas and Happy Holidays from RheumNow.  Dr. Jack Cush tells his podcast story - the genesis, keys to success and recommendations on how to get into podcasting - for teaching, practice, fun or influence.

Dr Jack Cush reviews the latest news, journal reports, regulatory approvals, plus 3 new cases from rheumatologists.

A moderated panel of prominent female rheumatologists will discuss the challenges and successes in clinical practice and research that they encountered during the COVID-19 pandemic.

The ACR 2021 meeting has concluded. Dr. Jack Cush recants a few more great abstracts from this past weeks meeting.

Drs. Jack Cush and Martin Bergman gather to review the topic of treat-to-target (T2T) management in rheumatology.  Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022. You can register and learn more about the meeting at: https://r-w-c-s.com/2022/

Dr. Jack Cush discusses the evolution and future of telemedicine in rheumatology with the telemedicine guru - Dr. Alvin Wells

Dr. Jack Cush interviews Professor Edward Keystone, MD (from the University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood.

An Interview with Dr. Kaleb Michaud on Abstract 1158 from #ACR21

ALPN-303 - Dr. Pedro Castillo Dr. Castillo reports on abstract #1429 presented at the ACR21 annual meeting.

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kay Infliximab Drug Monitoring in PsA, RA, AxSpA: Dr. Pedro Castillo Lupus and Pregnancy: Dr. Sheila Reyes Secukinumab Effect on CV Risks in PsA, axSpA: Dr. Sheila Reyes

Spondyloarthritis Roundtable Rehash of ACR 2021

Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie

Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao

The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell

Tofacitinib and Malignancy Risk: Dr. Seoyoung Kim Potpourri of Biosimilar Trials: Dr. Jonathan Kay Closing a Chapter: Interview with the 84th ACR President 2020-2021, Kathryn Dao

RheumNow Rheumatology Roundup- Drs.  Kavanaugh and Cush

TNF Inhibitor Panel Discussion- ACR21 Annual Meeting

Psoriatric Arthritis Panel Discussion- ACR21